Unravel Biosciences, Inc.
Unravel Biosciences is dedicated to transforming drug development for complex disorders by clinically derisking new targets using existing drugs. Their mission is to accelerate the discovery of effective treatments, ensuring all patients have access to safe and effective therapies. They leverage deep science, AI-powered patient data, and innovative platforms like BioNAV and rareSHIFT to rapidly identify therapeutic mechanisms and develop new therapies. Their work includes clinical trials, collaborations, and a focus on rare diseases such as Rett syndrome and Pitt Hopkins syndrome.
Industries
Nr. of Employees
small (1-50)
Unravel Biosciences, Inc.
196 Boston Ave, Suite 1000, Medford, MA 02155
Products
Repurposed histone deacetylase inhibitor formulation (clinical-stage) for neurodevelopmental disorders
A reformulated, clinical trial material of an existing histone deacetylase inhibitor adapted for clinical testing in neurodevelopmental disorders following computational nomination and preclinical validation.
Home RNA collection kit for remote patient sampling
A swab-based kit designed to enable patients worldwide to self-collect RNA samples suitable for sequencing and molecular analysis.
Repurposed histone deacetylase inhibitor formulation (clinical-stage) for neurodevelopmental disorders
A reformulated, clinical trial material of an existing histone deacetylase inhibitor adapted for clinical testing in neurodevelopmental disorders following computational nomination and preclinical validation.
Home RNA collection kit for remote patient sampling
A swab-based kit designed to enable patients worldwide to self-collect RNA samples suitable for sequencing and molecular analysis.
Services
Integrated service that collects patient RNA remotely, performs molecular analysis and in-silico prioritization, validates candidates in in vivo and rodent models, and supports clinical translation and trial execution in partnership with foundations and clinicians.
Remote collection kit deployment and RNAseq generation to produce clinical-grade molecular datasets for rare and complex disorders.
Clinical trial design, outcome measure validation, localized clinical tool translation, and assistance with patient recruitment and trial execution.
Integrated service that collects patient RNA remotely, performs molecular analysis and in-silico prioritization, validates candidates in in vivo and rodent models, and supports clinical translation and trial execution in partnership with foundations and clinicians.
Remote collection kit deployment and RNAseq generation to produce clinical-grade molecular datasets for rare and complex disorders.
Clinical trial design, outcome measure validation, localized clinical tool translation, and assistance with patient recruitment and trial execution.
Expertise Areas
- Patient-centered RNA-based discovery
- Systems-biology network modeling
- In-silico high-throughput screening
- Preclinical in vivo screening (small whole-organism and rodent models)
Key Technologies
- RNA sequencing (RNAseq) from non-invasive swabs
- Probabilistic network models / foundation models
- AI-driven in-silico compound screening
- Systems biology and molecular network inference
News & Updates
A partnership to accelerate the identification of potential drug candidates across multiple ultra-rare diseases.
A collaboration to test the safety and efficacy of RVL-001 in Colombia.
The FDA has granted orphan drug designation to RVL-001 for Rett syndrome, supporting its clinical development.
Unravel Biosciences received FDA Orphan Drug Designation for RVL-001 as a treatment for Rett syndrome.
A partnership to accelerate the identification of potential drug candidates across multiple ultra-rare diseases.
A collaboration to test the safety and efficacy of RVL-001 in Colombia.
The FDA has granted orphan drug designation to RVL-001 for Rett syndrome, supporting its clinical development.
Unravel Biosciences received FDA Orphan Drug Designation for RVL-001 as a treatment for Rett syndrome.